FeesSafety
Pluang+

NervGen advances Phase 3 trial for spinal cord injury drug NVG-291 with FDA Breakthrough Therapy status

Company Fundamentals
16 Nov 2026, 14:15 WIB
GlobeNewsWire
View Source
Bullish
NervGen advances Phase 3 trial for spinal cord injury drug NVG-291 with FDA Breakthrough Therapy status

NervGen Pharma reported Q3 2026 results and updates on its Phase 3 RESTORE study for NVG-291, a drug targeting chronic spinal cord injury. The FDA granted NVG-291 Breakthrough Therapy designation, highlighting its potential based on early clinical data. Enrollment in the RESTORE study is ongoing, with topline results expected in the first half of 2028. The company has strong cash reserves to fund operations through this period and is preparing regulatory and clinical milestones to support future drug approval and expansion.

NervGen Pharma's Q3 2026 financial results and business updates provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 16, 2026 18:12 WIB: out of 150 priced health-sector US stocks, 66 rose and 50 fell today. Notable movers include Summit Therapeutics Inc (SMMT) at USD 11.52 with a 1-day change of -18.59% and a typical hold time of 19 days, Abeona Therapeutics Inc (ABEO) at USD 2.28 down 5.79% with a 22-day hold, and Enveric Biosciences Inc (ENVB) at USD 1.58 up 4.29% with a 16-day hold time.

More News

Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics announced a 38% year-over-year revenue increase for Q3 2026, driven by its IC Drone insulator-cleaning activities. The company expanded its IC Drone platform into Greece through a strategic collaboration with CRONOS, identifying potenti...

Company Fundamentals
Bullish
32 minutes ago
Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo plc and Curio Legacy Ventures announced a collaboration to supply recycled nuclear materials for mixed-oxide (MOX) fuel production at Newcleo's planned US fuel manufacturing facility. This partnership combines Curio's NuCycle recycling techno...

Market News
Bullish
32 minutes ago
Heineken repurchases over 10 million shares in €1.5 billion buyback program's second tranche

Heineken repurchases over 10 million shares in €1.5 billion buyback program's second tranche

Heineken N.V. has repurchased a total of 10,017,690 shares under the second €750 million tranche of its €1.5 billion share buyback program as of November 13, 2026. The shares were bought both on the exchange and from Heineken Holding N.V., with an av...

Company Fundamentals
Neutral
1 hour ago
eGain launches service to prepare enterprise knowledge for reliable AI use without replacing platforms

eGain launches service to prepare enterprise knowledge for reliable AI use without replacing platforms

eGain Corporation introduced the Trusted Knowledge Service, designed to make existing enterprise knowledge AI-ready and reliable without replacing current platforms like SharePoint and Salesforce. The service includes evaluation, preparation, verific...

Market News
Bullish
1 hour ago
eGain launches Trusted Knowledge Service to prepare enterprise data for reliable AI use without platform changes

eGain launches Trusted Knowledge Service to prepare enterprise data for reliable AI use without platform changes

eGain Corporation has introduced the Trusted Knowledge Service, designed to prepare and certify enterprise knowledge for AI use without replacing existing platforms like SharePoint and Salesforce. The service includes assessment, correction, certific...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App